Skip to content
Clinical Trials – home

Tartu University Hospital

Verified siteinfo

Estonia A006, L. Puusepa Tn 8, 50406 Tartu, Estonia

  • 34 trials recruiting
  • Acute myeloid leukaemia · Arteriosclerosis · Bladder cancer
  • Adults and children

About Specializations

Tartu University Hospital in Tartu, Estonia specialises in clinical trials of conditions such as Acute myeloid leukaemia, Arteriosclerosis, Bladder cancer, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms and Cancer Research at Tartu University Hospital

The Cancer Centre is involved in clinical research on advanced tumors and glioblastoma multiforme, focusing on neoplasms and new ways to improve patient outcomes.

  • Testing new treatment approaches for newly diagnosed glioblastoma
  • Evaluating whether adding novel therapy to standard care can improve survival in advanced cancer
  • Studying overall survival and treatment effectiveness in aggressive brain tumors

This work reflects a strong interest in finding better options for difficult-to-treat cancers, especially where current therapies may have limited benefit.

Immune System Diseases and Dermatology

Research at the site includes immune system diseases such as moderate and severe atopic dermatitis, with studies designed to assess how well new therapies control symptoms and improve quality of life.

  • Assessing the safety and effectiveness of targeted treatment for atopic dermatitis
  • Exploring better symptom control in patients who need systemic therapy
  • Supporting improved care for chronic inflammatory skin disease

The focus is on helping patients with persistent eczema-like inflammation by testing therapies that may offer stronger and more consistent relief.

Otorhinolaryngologic Diseases and Chronic Rhinosinusitis

Clinical trials in otorhinolaryngologic diseases are addressing chronic rhinosinusitis with nasal polyps, aiming to reduce inflammation and improve nasal symptoms in people with long-term sinus disease.

  • Testing a new biologic approach for CRSwNP
  • Measuring changes in nasal polyp burden and symptom scores
  • Improving treatment options for patients with non-type 2 sinus inflammation

This area of research is centered on finding more effective ways to manage a condition that can significantly affect breathing, smell, and daily comfort.

Cardiovascular Diseases and Heart Failure

The site is also studying cardiovascular diseases, particularly heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction linked to systemic inflammation.

  • Evaluating whether a new anti-inflammatory therapy can lower cardiovascular risk
  • Studying prevention of heart failure events and cardiovascular death
  • Improving treatment strategies for patients with inflammatory heart disease

These trials aim to refine care for people living with complex forms of heart failure, where inflammation may play an important role in disease progression.

Bacterial Infections and Hospital-Acquired Infections

Research in bacterial infections includes studies of nosocomial infection and pneumonia, with a focus on improving the safety and tolerability of antibacterial treatment.

  • Assessing treatment options for hospital-acquired pneumonia
  • Evaluating safety in patients with serious bacterial infections
  • Supporting better infection control and treatment in vulnerable patients

This work helps inform more effective antibiotic use for infections that can be especially challenging in hospital settings.

Virus Diseases and Influenza Prevention

The trial portfolio also covers virus diseases, including research involving healthy individuals and people with stable conditions that raise the risk of influenza complications.

  • Studying immune responses to influenza vaccination
  • Comparing vaccine performance across different formulations
  • Improving protection for older adults and higher-risk groups

This research supports better prevention strategies against seasonal flu by examining how well vaccines stimulate immunity in important patient groups.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
A006, L. Puusepa Tn 850406 TartuEstonia
Recruiting now
34 trials
Conditions studied
79
Partner status
Verified site

More sites in TartuEstonia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

106 clinical trials

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Bladder cancer

Recruiting

Long‑Term Follow‑Up of Mitomycin (UGN‑103) Treatment in Patients with Recurrent Low‑Grade Intermediate‑Risk Non‑Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:Odense University Hospital

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Obesity+1

Recruiting

Semaglutide and Granisetron for Tolerability in Overweight Adults Without Diabetes

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Granisetron
  • Sponsor:University Of Tartu
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.